Vektor Medical, a San Diego, CA-based non-invasive, AI-based arrhythmia analysis technology company, raised $16m in Series A funding.
The round was co-led by Solas BioVentures and TVM Capital Life Science.
The company intends to use the funds for the commercialization of vMap®, Vektor’s AI-based arrhythmia analysis tool. To bolster this expansion, Vektor will increase clinical support and drive additional clinical studies to showcase the technology’s impact and inform future innovation as well as continue efforts to secure reimbursement.
Led by Rob Krummen, CEO, Vektor Medical develops AI-based, non-invasive arrhythmia analysis technology, vMap, which aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. vMap is an FDA-cleared, non-invasive AI-based solution for arrhythmia localization and analysis, utilizing a 12-lead ECG. It provides information to a physician to better understand arrhythmia sources and unlock actionable insights, enabling physicians to streamline their procedures and more appropriately treat their patients.